Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Up 3.1% – Still a Buy?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) shot up 3.1% on Tuesday . The company traded as high as $13.80 and last traded at $13.80. 8,827 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 41,049 shares. The stock had previously closed at $13.39.

Analysts Set New Price Targets

Separately, HC Wainwright raised their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd.

Greenwich LifeSciences Price Performance

The business’s 50 day simple moving average is $14.08 and its 200 day simple moving average is $14.49. The company has a market capitalization of $175.04 million, a price-to-earnings ratio of -19.07 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.20). As a group, analysts expect that Greenwich LifeSciences, Inc. will post -0.81 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Snehal Patel acquired 5,500 shares of the company’s stock in a transaction on Monday, August 5th. The shares were bought at an average cost of $13.18 per share, with a total value of $72,490.00. Following the purchase, the chief executive officer now owns 5,532,602 shares of the company’s stock, valued at $72,919,694.36. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders purchased a total of 8,800 shares of company stock valued at $120,665 over the last three months. 52.86% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of institutional investors have recently added to or reduced their stakes in GLSI. Rhumbline Advisers acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $117,000. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the second quarter valued at $264,000. Finally, Vanguard Group Inc. boosted its position in shares of Greenwich LifeSciences by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock worth $4,449,000 after purchasing an additional 1,420 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.